In times of uncertainty, it’s said “better the devil you know than the devil you don’t.”
Since the election, the prevailing sentiment in the drug industry has been just the opposite. The reversal of the old adage explains the industry’s reaction to Donald Trump’s election: a rally of almost 10 percent since Nov 8.
“It was not so much of an issue of, ‘Well, we know what we’re getting on both sides, and we prefer a Trump administration,’” said Ron Cohen, CEO of Acorda Therapeutics and executive committee chair of the industry group BIO. “It’s that we’re not exactly sure what we’re getting with a Trump administration, and it’s fairly clear what the implications would be of a Clinton administration.”
